

## Phospho-CDK7(T170) Antibody

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP3068a

## **Specification**

## Phospho-CDK7(T170) Antibody - Product Information

Application IHC-P, DB, WB,E

Primary Accession P50613
Other Accession Q03147

Reactivity Human, Mouse

Predicted Mouse
Host Rabbit
Clonality Polyclonal
Isotype Rabbit IgG

### Phospho-CDK7(T170) Antibody - Additional Information

#### **Gene ID 1022**

#### **Other Names**

Cyclin-dependent kinase 7, 39 kDa protein kinase, p39 Mo15, CDK-activating kinase 1, Cell division protein kinase 7, Serine/threonine-protein kinase 1, TFIIH basal transcription factor complex kinase subunit, CDK7, CAK, CAK1, CDKN7, MO15, STK1

### Target/Specificity

This CDK7 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding T170 of human CDK7.

### **Dilution**

IHC-P~~1:50~100 DB~~1:500 WB~~1:1000

E~~Use at an assay dependent concentration.

#### **Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

#### Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

## **Precautions**

Phospho-CDK7(T170) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

#### Phospho-CDK7(T170) Antibody - Protein Information



## Name CDK7

#### Synonyms CAK, CAK1, CDKN7, MO15, STK1

Function Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription (PubMed: 9852112, PubMed: 19136461, PubMed: 26257281, PubMed: 28768201). Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed: 9372954, PubMed: 9840937, PubMed: 19136461, PubMed: 26257281, PubMed: 28768201). Initiates transcription by RNA polymerase II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive C- terminal domain (CTD) when POLR2A is in complex with DNA, promoting dissociation from DNA and initiation (PubMed: 19136461, PubMed: 26257281, PubMed: 28768201). CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the CTD of POLR2A, allowing its escape from the promoter and elongation of the transcripts (PubMed: 9852112). Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition.

#### **Cellular Location**

Nucleus. Cytoplasm. Cytoplasm, perinuclear region. Note=Colocalizes with PRKCI in the cytoplasm and nucleus (PubMed:15695176). Translocates from the nucleus to cytoplasm and perinuclear region in response to DNA-bound peptides (PubMed:19071173).

Tissue Location Ubiquitous.


#### Phospho-CDK7(T170) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

## Phospho-CDK7(T170) Antibody - Images






Western blot analysis of extracts from Hela and MCF-7 cells, untreated or lamda phosphatase-treated, using Phospho-CDK7(T170) Antibody (upper) or Beta-actin (lower).




Western blot analysis of lysates from NIH/3T3 cell line, untreated or treated with  $\lambda$  phosphatase, using 459667101(Cat. #AP3068a)(upper) or Tubulin (lower).



Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody,



which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.



Dot blot analysis of Phospho-Cdk7-T170 Pab (Cat. #AP3068a) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.

## Phospho-CDK7(T170) Antibody - Background

The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression. This protein forms a trimeric complex with cyclin H and MAT1, which functions as a Cdk-activating kinase (CAK). It is an essential component of the transcription factor TFIIH, that is involved in transcription initiation and DNA repair. This protein is thought to serve as a direct link between the regulation of transcription and the cell cycle.

# Phospho-CDK7(T170) Antibody - References

Zhou, M., et al., Proc. Natl. Acad. Sci. U.S.A. 100(22):12666-12671 (2003). Kino, T., et al., Biochem. Biophys. Res. Commun. 298(1):17-23 (2002). Schneider, E., et al., Oncogene 21(33):5031-5037 (2002). Nekhai, S., et al., Virology 266(2):246-256 (2000). Zhou, M., et al., Mol. Cell. Biol. 20(14):5077-5086 (2000).